Merck Receives EU CHMP Opinion For KEYTRUDA As Adjuvant Treatment For Adults With Non-small Cell Lung Cancer At High Risk Of Recurrence Following Complete Resection And Platinum-Based Chemotherapy

Benzinga · 09/15/2023 13:11

Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial